Hint mode is switched on Switch off
For swift navigation between sections

Denali Therapeutics
LEI 549300ZTQ2HO18L3Q830

PDF download

Choose all Reset all
Download Cancel
Organization name
Denali Therapeutics Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Awards

News

27/07/2026 Denali Therapeutics: Completion Of Acquisition Or Disposition Of Assets, Financial Statements And Exhibits
12/06/2026 Denali Therapeutics: Regulation Fd Disclosure, Financial Statements And Exhibits
23/05/2026 Denali Therapeutics (NASDAQ: DNLI) Stock Analysis: Navigating Setbacks and Seizing Growth Opportunities
21/05/2026 Denali Therapeutics: (including Exhibit 99.1) Shall Not Be Deemed “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liabilities Of That Section, Nor Shall It Be Deemed Incorporated By Reference Into Any Filing Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Expressly Set Forth By Specific Reference In Such A Filing, Financial Statements And Exhibits
27/03/2026 Denali Therapeutics: Of The Form 8k Filed By Denali Therapeutics Inc. (the “company”) On December 4, 2025 Related To The Synthetic Royalty Funding Agreement Between The Company And Royalty Pharma (the “royalty Agreement”), And The Information Contained In Item 7.01 Below, Is Hereby Incorporated By Reference Into This Item 2.03 In Its Entirety, Regulation Fd Disclosure
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
II q eng
2025
I q eng
II q eng
III q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
Show more Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300ZTQ2HO18L3Q830
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001714899
  • EIN
    46-3872213
Registration is required to get access.